Related Experiment Video

Updated: May 10, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

18.8K

Improving antifungal lipid-based drug delivery against Candida: a review

Gabriel Davi Marena1,2, Alba Ruiz-Gaitán3,4, Taís Maria Bauab1

  • 1Department of Biological Sciences, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil.

Expert Opinion on Drug Delivery
|October 29, 2024
PubMed
Abstract

Insights

Lipid-based nanosystems offer a promising approach to combat rising fungal infections, especially those caused by drug-resistant Candida strains. These advanced delivery systems aim for targeted and sustained release of antifungal medications.

Area of Science:

  • Mycology
  • Nanotechnology
  • Pharmacology

Background:

  • Fungal infections, particularly by Candida species, are increasing, exacerbated by the COVID-19 pandemic and the rise of antifungal resistance.
  • Limited therapeutic options for antifungal treatments pose significant challenges in managing these infections.

Purpose of the Study:

  • To review recent advancements in lipid-based nanosystems for antifungal drug delivery.
  • To evaluate the potential of these nanocarriers in targeting resistant Candida strains and improving treatment outcomes.

Main Methods:

  • Comprehensive analysis of recent scientific literature on lipid-based nanosystems for antifungal applications.
  • Evaluation of studies focusing on the characterization and therapeutic potential of these nanomaterials against resistant fungal pathogens.

Main Results:

  • Lipid-based nanosystems demonstrate potential for controlled and sustained release of antifungal agents.
  • These systems show promise in specifically targeting resistant Candida strains, offering a novel therapeutic strategy.

Conclusions:

  • Lipid-based nanomaterials represent a promising alternative for treating challenging fungal infections, including those caused by multidrug-resistant strains.
  • Further research and clinical development are crucial to translate nanomedicine innovations into effective patient treatments for fungal diseases.
Keywords:
Candida sppantifungalscontrolled releaseinfectionlipid system

More Related Videos

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis09:44

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis

Published on: June 13, 2021

2.7K
Quantifying the Antifungal Activity of Peptides Against Candida albicans06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

2.2K

Related Concept Videos

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
Bioavailability Enhancement: Drug Solubility Enhancement01:16

Bioavailability Enhancement: Drug Solubility Enhancement

Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...